BIOMARKERS FOR GOSSYPOL CHEMOTHERAPY AND METHODS OF TREATING DISEASE
    9.
    发明申请
    BIOMARKERS FOR GOSSYPOL CHEMOTHERAPY AND METHODS OF TREATING DISEASE 审中-公开
    生物标记物治疗疾病和治疗疾病的方法

    公开(公告)号:US20120302629A1

    公开(公告)日:2012-11-29

    申请号:US13388610

    申请日:2010-07-28

    摘要: The present invention provides a biomarker for selecting a patient for treatment with gossypol, wherein the biomarker comprises an elevated expression level of c-Myc, Mcl-1, or combination thereof, relative to the normal expression level of c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for targeting patients for treatment with gossypol, wherein the patient has a disease, condition, or disorder that overexpresses c-Myc, Mcl-1, or combination thereof. The present invention also provides methods for treating or ameliorating a disease, condition, or disorder in a patient comprising determining the expression level of c-Myc, Mcl-1, or combination thereof in the patient and administering gossypol to the patient. In certain embodiments of the invention, the disease is cancer, and the cancer cells show elevated expression levels of c-Myc compared to non-cancerous cells. The invention also provides methods for overcoming Mcl-1-mediated chemoresistance comprising administering gossypol to a patient in need thereof.

    摘要翻译: 本发明提供了一种用于选择用棉酚处理的患者的生物标志物,其中相对于c-Myc,Mcl-1的正常表达水平,生物标志物包含c-Myc,Mcl-1或其组合的升高的表达水平 ,或其组合。 本发明还提供了靶向患者用棉酚治疗的方法,其中患者具有过表达c-Myc,Mcl-1或其组合的疾病,病症或病症。 本发明还提供了用于治疗或改善患者疾病,病症或障碍的方法,包括确定患者中c-Myc,Mcl-1或其组合的表达水平,并向患者施用棉酚。 在本发明的某些实施方案中,该疾病是癌症,与非癌细胞相比,癌细胞表现出c-Myc的升高的表达水平。 本发明还提供克服Mcl-1介导的化学耐药性的方法,包括向有需要的患者施用棉酚。